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Abstract: 
5-folourouracil (5-Fu) commonly use in the treatment of different kinds of cancer, but limited 
cellular uptake and death is still a problem. Herein, we report a simple process for the synthesis 
of pressure-sensitive nanogels that indicate to be appropriate in the delivery of 5-Fu. The 
hydrogels (Al-CD) prepare by crosslinking of alginate (Al) with modified beta Cyclodextrin (β-
CD) as Crosslinker. Next, nanoparticles obtaine by an emulsification method. 5-Fu as model 
drug loades into the Al-CD nanogels easily by mixing it in aqueous solution with the 
nanoparticles. The results reveale that the Al-CD nanogels are cytocompatible. They also have a  
noticeable drug encapsulation (82.1 ±5.7%) while they can release (in vitro controlled) 5-Fu in 
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conditions that imitate the intravascular pressure conditions. These nanogels can rapidly be taken 
up by HT-29 cells (a colon cell line). Additionally, a higher 5-Fu intracellular accumulation and 
a significant cell death extension by apoptosis mechanism is notice when compare with free 5-
Fu. Accordingly, the developed nanogels can be employe as an excellent candidate to overcome 
the inefficiency of 5-Fu in anticancer treatments and possibly can employe for further evaluation 
as a chemotherapical agent in applications beyond cancer. 
Keywords: Cyclodextrin; Crosslinked alginate hydrogel; Nanoparticles; 5-Fluorouracil (5-FU); 
Apoptosis. 
Introduction: 
Cancer is one of the most serious causes of death worldwide. Among different kinds of cancer, 
colorectal cancer (CRC) was ranked as the fourth leading reason of cancer-related death for both 
men and women worldwide in 2008, 1.2 million new CRC cases and 0.6 million deaths(1). In the 
same vein, chemotherapy as one of the main common methods for the treatment of the cancer, 
this deadly malady, is gaining researchers’ particular attention and support. 
 The problem lies in the fact that although chemotherapy is an effective method against cancer, 
most of available chemotherapeutic medicines kill both cancerous cells and normal ones 
resulting in serious unavoidable toxicity and side effects(2).  Moreover, many anticancer drugs 
have serious problems with water-solubility and stability which reduce their bioavailability and 
clinical application. Researchers in this field have made attempts to address the above-mentioned 
problems regarding chemotherapeutic agents(3).  
Even though anti-cancer drugs are mostly prescribed at maximum tolerated dose to eliminate as 
many cancerous cells as possible, the efficiency of chemotherapy in preventing CRC progression 
to an advanced stage is unfortunately poor. The issue lies in anticancer drugs themselves as they 
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cannot reach cancer cells in effective and fatal concentrations. For instance, in case of oral 
administration, drug release, absorption, and metabolism in the stomach and small intestine 
diminish drug delivery to the colon(4). In addition, the colonic mucosa seems to be a further 
barrier to drug permeation and to reach cancer cells located in the colon membrane wall. Based 
on the clinical importance of oral anticancer drugs for colon cancer, different approaches have 
been investigated by researchers such as use of drug delivery systems (5-8). Colon delivery 
systems generally work founded upon the transit time in the upper gastrointestinal (GI) tract, 
sensitivity to colonic pH or increased peristaltic pressure in the colon(9, 10). The peristaltic 
pressure offers a more reliable “trigger” for drug delivery compared with transit time or pH 
change. This has been investigated by a variety of polysaccharide delivery devices including 
chitosan, gelatin and alginate in the form of hydrogel (11-16). 
Among different polysaccharides, the seaweed-derived alginate, which is a family of unbranched 
copolymers, is composed of alternating blocks of 1-4 linked -l-guluronic acid (G-block) and -D-
mannurunic acid (M-block) residues. These have been widely investigated for the production of 
pharmaceutical dosage forms involving colon delivery devices. The copolymer can be cross-
linked in aqueous media to produce a hydrogel at room temperature through ionic interactions 
with multivalent cations (e.g., Ca
2+
, Al
3+
)(17). Alginate can prepare a compact gel at low gastric 
pH that hinders drug release. However, the hydrogel swells  while it is slowly eroded in 
dissolution media by replacing the multivalent cations with physiological ions such as Na
+
 and 
K
+
, resulting in  gradual release of the loaded drug(18). Rahman et al., (19)produced alginate 
spheres containing 5-FU which is coated with Eudragit S100, dissolving  at pH 7.0, and avoiding 
drug release in the higher GI tract.  
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5-Fluorouracil (5-FU) is one of the most commonly used chemotherapy drugs in anticancer 
therapy. It has become valuable in dealing with variety of human malignancies including 
gastrointestinal cancer, breast cancer and head and neck cancer(20).  The common administration 
of 5-FU is intravenous (IV) injection. After IV injection, 5-FU is carried via the blood circulation 
system to major organs of human body, such as liver, lung, heart and kidney, resulting in wide 
systemic distribution and therefore decreased effective concentration of drug in target tissues 
with extreme side effects. However, the metabolism of drug can reduce the effective 
concentration of drug delivered to the colon. It has been reported that up to 85% of injected 5-
fluorouracil (5-FU), is quickly converted by Dihydropyrimidine dehydrogenase to inactive agent, 
resulting in a half-life of 10–15 min for 5-FU (21-25). The inconvenience and worry about IV 
drug using via injection are further disadvantages of 5-FU administration. However, the oral 
drug delivery of 5-FU reduces delivered dosage of drug to the colon based on drug release, 
absorption, and metabolism in the stomach and small intestine(26). He et al.(27) mentioned that 
after oral administration of 5-FU pellets in rats, 5-FU concentrations in the stomach and intestine 
could reach 90 and 11 mg/g tissue, respectively.While the concentrations in the cecum and colon 
were <1 mg/g, either for tissue or content. According to these results, there is an urgent need to 
develop an ideal formulation to load 5-FU efficiently in order to overcome some of the above 
mentioned drawbacks. This includes the fabrication of nanoparticles (NPs) formulation that 
would efficiently encapsulate and sustain released 5-FU (11, 28-30). A potential restriction of 
common controlled drug-delivery systems is that they have been planned to function under static 
conditions. However, mechanically dynamic conditions are the norm of many positions in the 
body (e.g., compression in cartilage and bone, tension in muscle and tendon, and shear force in 
blood vessels). Although many researchers have worked to develop drug-delivery systems, 
Page 4 of 37
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
5 
 
which actively respond to external stimuli such as temperature, pH, ultrasound, electric and 
magnetic fields, the pressure signals responsive hydrogels have not been systematically 
investigated as an external stimulation for controlled drug delivery in the  human body (31-33). 
In the present study, we investigate a new controlled release system based on alginate hydrogel 
compose of β-Cyclodextrin Crosslinker (Al-CD). Al-CD synthesis by adding the β-Cyclodextrin 
derivative junction point with alginate as a main chain polymer, which is sensitive to pressure 
stimulus. β-Cyclodextrin (β-CD) is a well-known polysaccharide which forms inclusion 
complexes with a variety of guests as host molecule. Therefore, β-CD has been extensively used 
as an excipient to improve the physicochemical and pharmaceutical properties of drug 
molecules. The major factors contributed to binding are supposed to be primarily van der Waals 
and hydrophobic interactions.  Briefly, the attraction of guest molecules towards β-CD mainly 
depends on conformity between the guest molecules and the β-CD cavity, which is based on the 
terms of van der Waals interactions owing to size and shape matched between the host and the 
guest. Since its potential energy is contrariwise proportional to the sixth power of the distance, 
small alteration and/or restriction in the molecular structure of β-CD may encourage a change in 
its ability to interact with a guest by applying an outside stress (34).An external stress or pressure 
application can bring about distortion and/or conformational restriction of β-CD moieties in Al-
CD  as a result of the β-CD-containing network. This decreases inclusion ability of the β-CD 
moieties leading to the guest release. 
 
In this study, the chemical structure of the prepared polymer was characterized by FT-IR and H-
NMR spectroscopy.  The synthesized polymer was then employed to prepare nanoparticles for 
encapsulation of 5-FU as a drug model. The TEM, FE-SEM and DLS techniques were used to 
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characterize the prepared particles size. In addition, drug loading via encapsulation efficiency 
nanoparticles was analyzed and the results were compared with 5-FU as control. In vitro 
investigation of 5-FU release from nanoparticles was carried out to evaluate nanoparticles with 
5-FU under pressure.  
2. Experimental: 
2.1 Materials 
Medium-molecular-weight alginate was obtained from Sigma-Aldrich (USA). β-cyclodextrin, 
Para toluene sulfonyl chloride (Tosyl Chloride), pyridine, 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC), N-Hydroxysuccinimide (NHS), Poly vinyl alcohol (PVA), Calcium 
chloride, Diethyl ether, Ethylene diamine, HPLC grade dimethylsulfoxide, sodium chloride, 
sodium azide, Absolute ethanol, hydrochloric acid ,Aerosol OT, methanol, methylene chloride 
and sodium hydroxide were purchased from Sigma-Aldrich (Switzerland). 5-FU was kindly 
gifted from Osve Pharmaceutical Co., Ltd. (Tehran, Iran).  
2.2 Preparation of Tri -O- Sulfonyl β- Cyclodextrin (CD-OTS) 
CD-OTS was prepared by the method previously reported with a slight modification(35). Briefly, 
2.2 gr of β-Cyclodextrin was dissolved in 22ml pyridine at 40 
°
C; then 1.2 gr of Tosyl Chloride 
was added. The reaction continued overnight. Then the reaction mixture was cooled at room 
temperature. The mixture purred suddenly in excess amount of diethyl ether. The precipitate was 
vacuum filtered and washed three times with acetone and dried in vacuum oven for 48 hr. 
2.3 Preparation of Sodium Alginate - β-Cyclodextrin Hydrogel (Al-CD) 
To prepare the hydrogel, first (Tris- deoxy- aminoethylamino) β-Cyclodextrin (CD-Crosslinker) 
was synthesized. In order to prepare the CD-Crosslinker, 3 gr CD-OTS which prepared 
previously, was added to 10ml of Ethylendiamine at 60 °C and stirred for 24hr (fig. 2), then 
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cooling to room temperature.  The CD-Crosslinker was prepared by precipitation of mixture with 
excess amount of ethanol. The product filtrated and washed with ethanol and dried in vacuum 
oven over night.  The hydrogel prepared by adding 0.6 gr EDC and 0.36 gr NHS to Sodium 
Alginate (AL) solution (1.8% w/w). The mixture was stirred for 15 min to pre activate the 
combination. Next, 0.68 gr CD-Crosslinker was added slowly. The mixture stirred vigorously 
with high speed stirrer and vacuum filtrate. Finally, the blend was allowed to dry at room 
temperature in Vacuum Oven for 24 hr. Alginate based hydrogels with different CD-Crosslinker 
content were prepared (Table I). 
2.4 Synthesis of Hydrogel nanoparticles 
Nanoparticles were prepared by emulsification crosslinking from the processes used in the 
previously mentioned procedure(36). Briefly, previously prepared polymer solution in water (1.0 
% w/v; 1 ml) was emulsified into freshly prepared Aerosol OT (AOT) solution in methylene 
chloride (5 % w/v; 1 ml), then solution sonicated for 1 min over an ice bath and then afterward 
15 ml of aqueous PVA solution (2 % w/v) was added to the above mentioned emulsion and again 
sonicated for at least 1 min over an ice bath to form a secondary water-in-oil-in-water emulsion. 
The emulsion then stirred using a magnetic stirrer, and 5 ml of aqueous calcium chloride solution 
(60 % w/v) was added drop wise to the emulsion. The emulsion was kept stirred with the 1000 
rpm at room temperature for about 18 h to evaporate methylene chloride. To preparing drug-
loaded nanoparticles, the drug (5 mg) was dissolved in the aqueous polymer solution, and the 
synthesis procedure continued the same as the above mentioned method. The formed 
nanoparticles were then collected from the solution by ultracentrifugation (SIGMA 3-16 K 
Centrifuge, UK) at 20,000g. Furthermore, the separated nanoparticles washed two times with 
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distilled water to remove excess PVA and the free drug. Finally, nanoparticles were freeze dried 
and stored at 4°C.  
2.5 Drug loading capacity and encapsulation efficiency  
Drug loading capacity (LC) (w/w %) of nanoparticles was determined according to the following 
formula. 
LC (%) = (mass of 5-FU extracted from freeze- dried nanoparticles)/ (total mass of freeze- dried 
nanoparticles) ×100 
 Firstly , the nanoparticles were freeze-dried and dissolved in ethanol and the 5-Fu  content of the 
nanoparticles was determined on an Agilent Technologies HPLC system (Agilent Technologies 
Inc, 1200, California, USA) equipped with a UV detector (Agilent Technologies Inc, 1200) and 
reversed phase column (ODS C18, 5 µm, 4.6 mm× 250 mm, Dikma, China). The mobile phase 
consisted of 70-30 Acetonitrile-water (v/v %), respectively. The mobile phase was pumped at a 
flow rate of 1.0 ml/min and 5-FU concentration was measured at 279 nm.  
Encapsulation efficiency (EE) of nanoparticles was calculated according to the following 
formula: 
EE % = (Total amount of 5-FU inside Nanoparticles)/ (Total amount of 5-FU in collected 
nanoparticles)  
2.6 In vitro drug release  
In vitro release of encapsulated 5-FU from the nanoparticles was measured under sink conditions 
(volume of release medium used was enough to dissolve at least five times the quantity of the 
drug present in nanoparticles). Briefly, 100 mg of nanoparticles was dispersed in 10ml of 
phosphate-buffer saline (PBS, pH 7.4) and placed into a dialysis bag with molecular weight 
cutoff of 12000 D (Sigma, Germany). The dialysis bag was placed in a flask containing 100 ml 
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of release medium (PBS), pH 7.4) (sink condition). The whole assembly was shaken at 100 rpm 
and 37˚C. At the predetermined time intervals, 5 ml of the release medium was removed and 
replaced with the fresh medium. The content of 5-FU in the medium was measured by HPLC. 
The cumulative release percentage of 5-FU was calculated and compared with the CLE used as 
control. 
 The Kinetic  of  drug release from the nanoparticles was  calculated  by  investigating  its related  
data  according  to  Korsmeyer-Peppas model: 
Mt/ M∞=Kt
n 
where  t   corresponds  to the  release  time  (min),  Mt / M∞ is a fraction of drug released at time 
t, k  is  a kinetic  constant  related  to  the  network  structure  and  n  is  a  diffusion  constant  
which  indicates  the  mechanism  of  release.  As the  similar  diffusion  constants  obtained  in  
all  the  release  assays,  no other  mathematical  models  were  applied. 
2.7 Release of 5-FU responsive to pressure 
In order to measure the effect of pressure on the release of nanoparticles, release was performed 
in sink condition which was described in 2.6, but putting pressure on the samples was an 
exception. Briefly, 100 mg of previously prepared nanoparticles was dispersed in 100 ml PBS, 
and then placed in cylindrical glass. The Glass was then covered with the PTFE door and sealed. 
The Cylindrical glass was equipped with three tubes, one for applying pressure (by exploiting the 
Nitrogen with computer control pump), one for extracting the samples and inserting the freshly 
PBS (4 way junction), and finally one for naming the pressure gage demonstrating the pressure. 
Pressure-resistant cell (cylindrical glass), immersed in a water bath to regulate and stabilize 
temperature (measured accuracy within 0.05°C) and placed on the stirred bar. The whole 
assembly was stirred at 100 rpm and 37˚C. The pressure inside the cell was generated and 
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released through a pump and was measured with a pressure gauge (measured accuracy within 2 
mmHg). A pump operated by computer was used to adjust and apply the cyclic pressure (fig. 1). 
At the predetermined time intervals, 5 ml of the release medium was removed and replaced with 
the fresh medium.  The pressure was kept constant throughout the experiment by applying 
Nitrogen throw by the computer controlled pump. The content of 5-FU in the medium was 
measured by HPLC as described previously. The cumulative release percentage of 5-FU was 
calculated and compared with the no pressured samples. 
2.8 Cytotoxicity study 
MTT assay was performed HT-29 cell line (National cell Bank of Iran, Pasteur Institute, Tehran, 
Iran)  in order to evaluate the cell cytotoxicity and viability of the Al-CD nanoparticles. Cells 
were seeded at a density of 1 × 104 cells/well onto 96-well plates (Nunc, Denmark) in Roswell 
Park Memorial Institute medium (RPMI) containing 10% fatal bovine serum (FBS) and 1% 
antibiotics (penicillin/amphotericin) for 24 hours in the incubator (in humidified atmosphere with 
5% CO2 at 37 ˚C). Cytotoxicity of the Al-CD nanogels was determined by standard MTT assay 
with an indirect extract process (ISO 10993-12). Briefly, Al-CD nanogels were treated in an 
autoclave (15 min at a pressure of 15 ponds and temperature of 121˚C), then removed in 
extraction medium (a RPMI with 10% FBS) for five days. The extract was gathered, and added 
to the full-growth media of confluent HT-29 cells to achieve three concentrations of 10, 25 and 
50 µg.ml
-1
 and incubated for 24 hr, then 100 µL PBS containing of 0.5 mg.ml
-1
MTT was added 
to each cell, and cells were once more incubated for 4 hr at 37 ˚C in CO2. Then the resulted 
formazan crystals were dissolved by solubilisation buffer. The optical density of the solution was 
measured at a wavelength of 545 nm.  
2.9 Induction of apoptosis 
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Apoptosis (programmed cell death) represents a major causative factor for the anticancer action 
of a drug (37, 38). Therefore, in the present study, flow cytometry was used to investigate 
whether apoptosis can bring about the cell death induced by drug loaded crosslinked alginate 
nanogels. 
Human colon cancer cell line HT-29 was pretreated with 5-FU loaded nanogels, pure Al-CD-3 
and free 5-FU for 24 hr, and was analyzed for various parameters of apoptosis. Annexin-V-
FLUOS staining assay was used to determine the plasma membrane alterations in cells. In order 
to prepare the cells for test, the cells were washed in PBS, resuspended in 100mL of binding 
buffer containing a FITC conjugated anti-annexin V antibody. They were then analyzed with a 
flow cytometer (FACS Calibur, Becton Dickinson, and Bedford, MA). A standard sample, 
10,000 cells per treatment condition, was analyzed by flow cytometry using an excitation 
wavelength at 488 nm and emission 610 nm. 
3. Result and discussion 
3.1 Characterization of synthesis polymer 
The synthesis of Al-CD consists of three steps, first, activation of the hydroxyl groups of β-CD 
by reacting with tosyl chloride Second, reaction of CD-OTS with ethylenediamine to prepare 
CD-Crosslinker. Thereafter, the carboxyl groups of Sodium alginate react with amino groups 
(NH2) of CD-Crosslinker to prepare the Al-CD (Fig.2). Different weight ratio of Sodium 
Alginate and β-Cyclodextrin were employed in order to optimize the hydrogel characteristics 
(Table I). 
Figure.3 represented the FT-IR spectra of CD, Tosylated β-CD (CD-OTS), CD-Crossslinker, 
Sodium alginate (Al) and prepared Al-CD. Infrared (IR) spectra were recorded on a Shimadzu 
8400S Spectrometer (Shimadzu 8400S FT-IR, Osaka, Japan) with a scanning range from 4000 to 
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400 cm
-1
.The FT-IR spectra of β-CD indicate the broad band at 3384 cm
-1
 which is assigned to 
the symmetric and asymmetric OH stretch. The peaks at 1157, 1080, and 1028 cm
-1
  refer to C-O 
stretching vibration of glucosidic bonds, C-O stretching vibration in cyclic alcohols, and C-O 
stretching vibration in primary alcohols, respectively (39). The assigned peaks for CD-OTS are 
as the following: stretching vibrations at 1637 and 1488 cm
-1
 corresponded to aromatic rings and 
the peaks at 1335 and 1155 cm
-1
 that are assigned to the symmetric and asymmetric SO2 
stretching. The FT-IR spectra of CD-Crosslinker show a broad peak at 3300-3500 cm
-1
 which 
can be assigned to O-H and N-H groups, the peak at 1560 cm
-1
 refers to the bending vibration of 
N-H groups  and the 1370 cm
-1
 corresponds to C-N stretching vibration. The FT-IR spectra of 
sodium alginate (Al) indicated a broad peak at 3422 cm
-1
 and the peaks at 1615 and 1416 cm
-1
 
which correspond to acidic and alcoholic O-H groups and asymmetric and symmetric stretching 
vibration of carboxylate ion salt, respectively. The FT-IR spectrum of final hydrogel shows the 
characteristic bands of amide for hydrogel at 1644 cm
-1
 for amide I and 1566 cm
-1
 for Amide II 
band that coupled with the C=O stretching vibration. 
1
H NMR analysis confirms the proposal hydrogel formation: 
1
H NMR CD-Crosslinker: (300 MHz, D2O, DSS) δ  = 2.57-2.66 (m, 12H, -NHCH2CH2NH2), 
2.70-3.01 (m, 6H,  -CH2(H-6’)-), 3.22-3.33  (m,  3H,  -CH(H-4’)-),  3.40-3.48  (m,  14H,  -
CH(H-2,H-2’)-,  -CH(H-5’)-, -CH(H-4)-), 3.72-3.80 (m, 19H, -CH(H-3,H-3’)-, -CH(H-5)-, -
CH2(H-6)-), 4.92 (bs, 7H, -CH(H-1, H-1’)-)  ppm.  
1
H  NMR  Al-CD: (300 MHz,  D2O,  DSS)  δ  = 2.7-2.8  (6H, CD-NCH2-), 2.8-3.01  (12H,  -
CH2-AL,  -CH2(CD, H-6’)-), 3.03-4.1 (Sugar  protons  (AL,  CD),  DOH),  4.9 -5.2  (CD,  
AL(anomeric  protons),  8.01 (-NHCO-AL) ppm. 
3.2 Differential Scanning Calorimetric (DSC) 
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Thermal analysis by DSC of polymers in different parts of synthesis procedures was undertaken 
using a Mettler-Toledo DSC821. Measurements were performed over the temperature range of 
0–400 
◦
C at a heating rate of 10
◦
C/min. On accounts of simple and interpretable spectra 
compared to many other characterization methods, the Differential Scanning Calorimetric (DSC) 
method has been largely developed for characterization of polymer materials. As it is detected in 
the DSC spectrum of the native alginate, the endothermic peak at 106 ˚C is ascribed to the water 
absorption related to the hydrophilic nature of the functional groups of native alginate(36). On 
the other hand, in the DSC spectrum of the CD, an endothermic peak at about 118 °C was 
observed due to dehydration process and an exothermic peak at about 246 °C was detected due to 
the oxidation of OH groups of sample. The endothermic peak shifted to the 115 °C and 
exothermic peak converted to endothermic at 206 °C respectively for CD-Crosslinker, These 
indicate that the number of OH groups was reduced. However, it exposed the substitution 
reaction with amino groups of ethylenediamine which took place on the OH group of CD. In 
addition, the exothermic peak at 281 °C was also observed as a consequence of the oxidation of 
amino group. DSC thermograms of final hydrogel indicate an endothermic peak at about 110 °C 
which is broader than alginate because of dehydration of water molecules that bind to CD 
molecules and alginate. They also represent two exothermic peaks at about 270 and 290 °C , 
which can  refer to  the oxidation of carboxyl group at AL and amino group at CD-Crosslinker, 
respectively. Figure. 4 DSC spectra of: A) Al, B) CD, C) CD-Crosslinker, and D) Al-CD 
(Hydrogel) 
3.3 Particle size and morphology of nanoparticles 
The dispersion and aggregation of nanoparticles are important for their application; hence, 
measuring of the particles size is always a mandatory procedure. Furthermore, particle size can 
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affect biological characteristics of nanoparticles and the sub-hundred nanometer particle size is 
supportive in the drug delivery systems, since nanoparticles in this size range have been shown 
to have higher cellular and tissue uptake (40, 41). The nanoparticle size in solution was analyzed 
by dynamic light scattering (DLS) using a Malvern Zetasizer Nano ZS. The particles size 
distribution spectrum for the Al-CD nanoparticles is represented in Figure. 5 that illustrate the 
average particle size of 55.1±5.1nm and polydispersity index (PDI) of 0.213.  
The FE.SEM image which illustrated the morphology and size of nanogels is represented in 
Figure. 6. The Figure. 6 shows that most of nanoparticles are in spherical shape with an average 
diameter <50 nm. TEM image in Figure. 7 indicate nanoparticles shapes are in agreement with 
the FE.SEM image in spherical morphology. The difference in average particle size measured by 
DLS might be observed because of the swelling of nanoparticles in the solution during the 
measurement. 
3.4 Drug loading and encapsulation efficiency 
Drug loading and encapsulation efficiency of the Al-CD is represented in (TableI) which 
demonstrates dependency on the Al-CD concentration. Increasing the concentration of CD from 
0.1 to 0.85 in the formulation of nanoparticles led to an increase in 5-FU encapsulation from 40 
to 88%. We found a non-linear relation between the amount of drug added to the formulation and 
encapsulation efficiency. The enhanced loading capacity of the nanogels for 5-FU was driven 
from CD-Crosslinkers that could operate as binding sites to involve and complex 5-FU within 
the CD-Crosslinkers cavities. This could be explained according to the contribution of 
hydrophobic-hydrophobic interaction between CD and the Drug. Raising the concentration of 
Al-CD, it was expected to increase the number of CD groups available for interaction with 5-FU 
and subsequently better drug entrapment in the nanoparticles. Nevertheless, in sample 5 high 
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crosslinking density decreased the loading efficiency of sample because the flexibility of 
nanoparticles was reduced flexibility of nanoparticles by increasing the crosslinker which 
resulted in a lower loading capacity for this sample (42, 43). 
In order to calculate drug loading capacity of nanogels, we used different concentrations of 
nanogel solution (Al-CD-4) and drug (5-Fu) (Table II). 
These data show that 1ml of Al-CD-4 solution (10000ppm) loaded 88.1% of 5-Fu (5000ppm) 
and this is the highest capacity of nanogels for loading 5-Fu because the increase in nanogel or 5-
Fu concentration does not show any significant change. 
These nanogels are made of Alginate and Cyclodextrin that both could load 5-Fu.Infact, there are 
two molecules which could load drug by encapsulation, entrapment, and inclusion complex. 
Other studies proved that modified polymers based on alginate have a high drug loading 
capacity, that is more than 70% for 5-Fu (44-46). 
    
3.5 In vitro drug release 
The application of Al-CD nanoparticles to deliver 5-FU was monitored by drug release rate. 
Release rate was calculated by the flowing formula: 
Cumulative 5‐FU release (%) = Cumulative amount of 5-FU released at time t/ initial amount of 
5‐FU×100 
Figure. 8 show that Al-CD-2 released 5-FU faster than Al-CD-3 in consequence of the lowest 
CD content and crosslinking degree. The same data procedure was investigated for Al-CD-4 for 
which the drug release was the slowest among three samples. An initial burst release of loaded 5-
FU was observed within the early hours that can be attributed to free drug molecule that attached 
to the surface of samples. In addition, no burst release was observed for samples and controls 
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during the initial period of investigation. Apparently, inclusion complexation of 5-FU with CD 
delayed the diffusion of 5-FU from the hydrogels. After the early burst release, the release rate 
reduced greatly for a certain amount of time. At this stage, the release rate was enhanced again 
until all loaded 5-FU was discharged. Particularly, the two samples Al-CD-3 and Al-CD-4 
followed the distinctive multiphasic release profile more. During the period of reduced release, it 
is understood that the 5-FU molecules were retarded by the durable binding of CD Crosslinkers. 
After the 200 hr, the release was enhanced because of the degradation of the nanogels by the 
medium of disbanding of the nanogel together with the drug. 
The release mechanism of 5- Fu drug was analyzed with the Korsmeyer-Peppas equation: 
Mt / M∞ = Kt
n
 
Where Mt/M∞ is the fractional amount of the 5-FU released at time t; n is the diffusion exponent 
indicating the release mechanism; and K is a characteristic constant of the system. From the 
slope and intercept of the plot of log (Mt/MN) vs. log t, kinetic parameters including n and K 
were calculated. 
(Table II) indicated that R
2
 is higher than 0.90 and also n is lower than 0.5 in all samples. It can 
be perceived that the 5-FU release kinetics was based on the Fickian diffusion. This Fickian 
behavior may offer that the 5-FU release from the nanoparticles is controlled by the drug 
diffusion process. Based on our results, we find that the majority of observed release is going to 
be due to diffusion of the entrapped drug molecules through the polymer membrane, and not due 
to the drug absorption in the polymer. We consider that after cross-linking the polymer captured 
drug solution and let the drug diffuses over time. Eventually, we think that because of 
degradation, more drug molecules in solution will have a chance to release. Thus we consider the 
drug release controlled by diffusion and degradation of polymer. 
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The study of drug release kinetics using the zero-order and first order kinetic models were 
carried out. The respective correlation coefficients (R) were determined by means of the 
linearization of dissolution profiles. It is found that the first-order kinetic model is more 
appropriate for nanoparticles (the one that presented a higher value of correlation coefficient) 
(Table III). 
The release of the drug which followed first order kinetics can be expressed by the following 
equation: 
dC/dt = ‐Kc 
Log C = log C0‐Kt/2.303 
Where K is the first order rate constant expressed in t
−1
, C0 is the initial concentration of drug, 
and t is the time. The data obtained are plotted as log cumulative percentage of drug released vs. 
time which would yield a straight line with a slope of −K/2.303 [51]. 
3.6 Release of 5-FU responsive to pressure 
Investigation for the releasing rate under the accelerated pressure compared to non-pressure 
release revealed that obvious changes in drug release rate can be attributed to binding and non-
binding of drug molecule by β-CD (Fig.9). These results illustrated that the connection mode of 
the β-CD residues within the nanogel structure plays an important role in drug release. It is very 
important to mention that the regulation of the host–guest interactions controlled the drug release 
rate in response to the pressure.The drug release from Al-CD can be increased by applying the 
pressure since it can change the inclusion ability of β-CD moieties. Generally, based on Le 
Chatelier's principle, molecules assembled with increased pressure reduces their total volume 
when the release is faster in comparison to non-pressure condition (30). Our investigation clearly 
indicates that the release rate of drug (5-FU) was monitored by different parameter such as 
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crosslinking density, β-CD content and active site of β-CD. However the binding ability of β-CD 
moieties in Al-CD can be one of important parameter in controlled release of drug from sample 
since applying pressure can change the release rate of sample. The pressure sensitivity of 
samples can be attributed to the β-CD groups that contained a molecular network. This network 
can interact with drug and release the drug by applying the pressure. Based on the ability of 
prepared sample for controlling release with stimulating factors, prepared sample can be used for 
promoting drug delivery. 
3.7 Cytotoxicity assay 
Cytotoxicity of Al-CD-3 on HT-29 cells was studied using MTT assay (fig. 10). As can be seen 
in Fig. 10 high viability (95-98% as compared to control) of HT-29 cells is significant when 
exposed to 10, 25 and 50 µg ml
-1
 of Al-CD-3. These results indicate that Al-CD-3 in this 
concentration range displays a nontoxic effect on HT-29 cells and they are biocompatible. 
3.8 Induction of apoptosis 
As shown in Figure. 11, cells exposed to Al-CD nanoparticles without drug have significant 
apoptosis since alginate does not exert any influence on cancer cells. However, a significant 
increase of apoptotic cells (66.3%- 43.36%) was observed in the cancer cell lines, upon exposure 
to loaded Al-CD nanoparticles samples 3 and 4, respectively in comparison with the free 5-Fu  
(33.51%) as control. The apoptosis mechanism was employed approximately two times more in 
this experiment because cellular uptake of 5-fu from nanoparticles was higher than the same 
concentrations of free 5-FU. 
It is clear that there were a higher percentage of cells showing apoptosis exposure to sample-3 
compared to the sample-4.This can be explained by the increased release of 5-FU within cancer 
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cells that can be attributed to the faster release of the drug from the nanoparticles acting on  their 
target drug release section. 
Although nanoparticles have a tendency to accumulate in cancer cells via passive targeting 
development, this passive strategy has restrictions because of its nonspecific delivery approach. 
However, when nanoparticles have polysaccharides parts, polysaccharide moieties can co-
operate definitely with the biological targets, e.g., lectins that have been found in the surface of 
malignant cells and cancerous tissues (47). Therefore, nanomaterial with polysaccharides 
structure could increase cellular uptake and cancer-targeting abilities (48). 
  In addition, based on Yang, et all, the increase in apoptosis can be traced to polysaccharides 
based nanoparticles (49). (The apoptotic data were listed in table IV. 
4. Conclusion 
In this study, we developed a formulation for preparation of Alginate-Crosslinked by modified β-
Cyclodextrin to improve the biocompatibility and to make it sensitive to pressure. Drug loaded 
nanoparticles were synthesized successfully and its potential to control delivery of 5-FU was 
investigated. The obtained nanoparticles were characterized via NMR, FT-IR, DSC, FE-SEM, 
DLS, and TEM. The 5-FU loaded nanoparticles showed a controlled drug released property. The 
complexation of 5-FU with β-CD crosslinkers largely increased the loading level of 5-FU in the 
nanoparticles. The complexation could also reduce the initial burst release effect. Later on, it can 
retard the releasing of the complex 5-FU for a certain period until the hydrogels started to 
degrade hydrolytically and all remained 5-FU was released. The data demonstrated that β-CD in 
the alginate-based hydrogels played a dual role as Crosslinker as well as a binding site for 
hydrophobic anti-cancer drug, which imparted promising drug loading and controlled release 
behavior to the hydrogels. 
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The nanogels displayed a high cytocompatibility and could effectively enhance apoptosis in HT-
29 cells. In summary, the usage of improved nanogels as carrier for 5-Fu delivery leads to a 
developed in vitro anticancer efficiency which could make them as promising nanoparticles for 
the proficient delivery of anticancer drugs. Moreover, the formed Al-CD nanogels presenting 
pressure-controlled drug release sensitivity could be applied as a suitable delivery system in 
brain cancer or adrenal tumors which experience raised intracranial pressure or raised ICP (50) 
and high blood pressure (51). 
 
 
 
Figure captions 
Fig. 1 Schematic of proposed device used for measuring the drug release from nanoparticles 
under pressure. 
Fig. 2 The process of Al-CD preparation. 
Fig. 3 Fourier transforms infrared spectra. 
Fig. 4 DSC spectra of: A) Al, B) CD, C) CD-Crosslinker, and D) Al-CD (Hydrogel). 
Fig. 5 The effective diameter and size distribution of encapsulated nanoparticles measured by 
particle size analyzer. 
Fig. 6 FE-SEM images of Al-CD nanoparticles. 
Fig. 7 TEM image of Al-CD nanoparticles that negative stained with 2% w/v uranyl acetate. 
Fig. 8 In vitro release of 5-FU from encapsulated nanoparticles for different sample preparation 
(Means ±S.D, n=4). 
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Fig. 9 comparison of in vitro release of 5-FU from AL-CD-3 sample without and under 180, 220 
and 240 mmHg pressure (Means ±S.D, n=4). 
Fig. 10 MTT assay: effect of (10, 25 and 50 µg ml 
-1
) of Al-CD-3 on the viability of HT-29 cell 
line for 24 hr. 
Fig. 11 apoptosis assay by FACS, A) HT-29 cells as control, B) Exposed cell to 10 µg/ml of free 
5-FU, C) Exposed cell to 10 µg/ml of Al-CD-3 without drug loaded, D) Exposed cell to Al-CD-3 
with 10 µg/ml of 5-FU drug loaded, E) Exposed cell to Al-CD-4 with 10 µg/ml of 5-FU drug 
loaded. 
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Table I. Different ratio of CD-Crosslinker and alginate used of synthesis Hydrogel and Drug 
loading and encapsulation efficiency of Al-CD nanoparticles (means ±S.D, n=5). 
 
 
Sample 
Alginate(gr) CD-
Crosslinker(gr) 
EDC(gr) NHS(gr)    Loading of drug 
% 
1 1.14 0.33 0.29 0.17 60.44±0.9 
2 0.1 0.51 0.45 0.27 81.98±1.6 
3 0.82 0.68 0.6 0.36 80.41±1.8 
4 0.65 0.85 0.75 0.45 88.1±2.1 
5 0.51 0.1 0.87 0.53 40.56±1.4 
 
Table II. Calculation of drug loading and encapsulation efficiency of different concentration of 
Al-CD-4 nanoparticles and 5-Fu. 
Volume of nanogels 
solution with10000ppm 
concentration(ml) 
Drug 
concentration(ppm) 
Drug Loading 
(%) 
Encapsulation 
efficiency (%) 
0.5 5000 40.48±0.8 80.96+1.5 
0.75 5000 33.22±0.9 83.06±1.02 
1 5000 29.37±0.9 88.10±1.5 
2 5000 20.76±1.6 83.06±2.01 
1 1250 8.19±0.7 73.72±1.08 
1 2500 15.88±1.26 79.44±1.6 
1 7000 35.82±2.17 87.31±2.5 
 
Table III. Calculation of kinetics and diffusion constant for 5-FU release from AL-CD 
nanoparticles using Korsmeyer-Peppas equation and zero order release. 
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sample Reaction condition Korsmeyer-Peppas 
model 
Zero order model 
  n K                   R
2 
K                      R
2 
AL-
CD2 
Simulated biologic 
Environment 
0.481 0.272           0.90 0.132             0.92 
AL-
CD3 
 0.481 0.251           0.91 0.131             0.93 
AL-
CD4 
 0.439 0.228           0.90 0.129             0.90 
 
Table IV. Apoptotic data extracted from flowcytometry analysis (means ±S.D, n=5). 
Sample Apoptosis (%) Necrosis (%) Secondary 
mechanism (%) 
Living cells (%) 
HT-29 cells as 
control 
0.41 0.2 3.74 85.84 
Al-CD-3 
without drug 
10.11 2.78 2.84 84.18 
Al-CD-3 loaded 
5-FU 
66.30 3.84 14.08 20.98 
Al-CD-4 loaded 
5-FU 
43.36 9.84 15.89 30.91 
Free 5-FU 33.51 9.77 5.50 51.21 
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